S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover

Heron Therapeutics (HRTX) Competitors

$2.60
-0.02 (-0.76%)
(As of 02/23/2024 ET)

HRTX vs. LRMR, JANX, NUVB, PRAX, STTK, XERS, PHAT, ME, WVE, and HROW

Should you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include Larimar Therapeutics (LRMR), Janux Therapeutics (JANX), Nuvation Bio (NUVB), Praxis Precision Medicines (PRAX), Shattuck Labs (STTK), Xeris Biopharma (XERS), Phathom Pharmaceuticals (PHAT), 23andMe (ME), Wave Life Sciences (WVE), and Harrow Health (HROW). These companies are all part of the "pharmaceutical preparations" industry.

Heron Therapeutics vs.

Heron Therapeutics (NASDAQ:HRTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, community ranking, profitability and analyst recommendations.

Heron Therapeutics received 627 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 68.85% of users gave Heron Therapeutics an outperform vote while only 58.14% of users gave Larimar Therapeutics an outperform vote.

CompanyUnderperformOutperform
Heron TherapeuticsOutperform Votes
652
68.85%
Underperform Votes
295
31.15%
Larimar TherapeuticsOutperform Votes
25
58.14%
Underperform Votes
18
41.86%

Heron Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 169.23%. Larimar Therapeutics has a consensus target price of $16.33, indicating a potential upside of 34.76%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heron Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Larimar Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

81.8% of Heron Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 6.4% of Heron Therapeutics shares are held by company insiders. Comparatively, 4.3% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Heron Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.

Larimar Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -97.45%. Heron Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Heron Therapeutics-97.45% N/A -53.07%
Larimar Therapeutics N/A -32.58%-28.97%

Larimar Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Heron Therapeutics$107.67M3.62-$182.02M-$0.96-2.71
Larimar TherapeuticsN/AN/A-$35.35M-$0.76-15.95

In the previous week, Larimar Therapeutics had 14 more articles in the media than Heron Therapeutics. MarketBeat recorded 16 mentions for Larimar Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.81 beat Larimar Therapeutics' score of 0.20 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Heron Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Larimar Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Heron Therapeutics beats Larimar Therapeutics on 9 of the 16 factors compared between the two stocks.


Get Heron Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRTX vs. The Competition

MetricHeron TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$390.18M$6.70B$5.19B$7.50B
Dividend YieldN/A2.66%2.85%3.86%
P/E Ratio-2.7117.75243.4118.56
Price / Sales3.621,204.743,356.65207.32
Price / CashN/A16.5299.7955.40
Price / Book23.644.554.404.60
Net Income-$182.02M$149.04M$115.30M$207.21M
7 Day Performance-9.41%1.07%0.88%-1.09%
1 Month Performance-2.99%9.45%7.02%3.27%
1 Year Performance14.04%4.11%10.09%5.59%

Heron Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LRMR
Larimar Therapeutics
3.086 of 5 stars
$8.74
+11.6%
$16.33
+86.9%
+94.9%$383.77MN/A-11.5026Analyst Report
Analyst Revision
News Coverage
High Trading Volume
JANX
Janux Therapeutics
2.0726 of 5 stars
$7.93
-7.9%
$28.33
+257.3%
+2.3%$366.13M$8.61M-5.3664News Coverage
NUVB
Nuvation Bio
3.1137 of 5 stars
$1.66
-5.7%
$5.17
+211.2%
-10.6%$363.44MN/A-4.3753Negative News
Gap Down
PRAX
Praxis Precision Medicines
1.0601 of 5 stars
$41.29
-7.5%
$94.67
+129.3%
-16.9%$362.94MN/A-1.22109Upcoming Earnings
STTK
Shattuck Labs
2.8796 of 5 stars
$8.46
-5.4%
$16.33
+93.1%
+102.9%$359.47M$650,000.00-3.78105News Coverage
XERS
Xeris Biopharma
4.0135 of 5 stars
$2.87
-2.7%
$4.67
+62.6%
+140.8%$396.40M$110.25M-6.38355News Coverage
Positive News
Gap Down
PHAT
Phathom Pharmaceuticals
1.9307 of 5 stars
$6.21
-3.3%
$23.00
+270.4%
+11.1%$355.52MN/A-1.63112Upcoming Earnings
Analyst Report
News Coverage
Gap Down
ME
23andMe
1.9618 of 5 stars
$0.74
-3.9%
$1.75
+137.0%
-77.4%$353.82M$299.49M-0.67769Gap Up
WVE
Wave Life Sciences
4.6188 of 5 stars
$3.54
-9.5%
$8.40
+137.3%
+3.8%$350.64M$3.65M-4.07250News Coverage
High Trading Volume
HROW
Harrow Health
1.9291 of 5 stars
$11.51
-1.8%
$38.80
+237.1%
-35.8%$404.23M$88.60M-25.58182Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:HRTX) was last updated on 2/25/2024 by MarketBeat.com Staff